1. Etanercept treatment-related c-ANCA-associated large vessel vasculitis
- Author
-
Michael Rozenbaum, Nina Boulman, Lisa Kaly, Ofrat Katz Beyar, Itzhak Rosner, Gleb Slobodin, Doron Rimar, and Shira Ginsberg
- Subjects
Radiography, Abdominal ,medicine.medical_specialty ,C-ANCA ,030204 cardiovascular system & hematology ,Antibodies, Antineutrophil Cytoplasmic ,Etanercept ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Prednisone ,Rheumatic Diseases ,Internal medicine ,Large vessel vasculitis ,medicine ,Humans ,Spondylitis, Ankylosing ,Aortitis ,Aged ,030203 arthritis & rheumatology ,Ankylosing spondylitis ,Tumor Necrosis Factor-alpha ,business.industry ,General Medicine ,medicine.disease ,Immunology ,Female ,Rituximab ,Tomography, X-Ray Computed ,Vasculitis ,business ,medicine.drug - Abstract
Anti-tumor necrosis factor (TNF) agents have become central players in the management of autoimmune and rheumatic disease. With the wide use of anti-TNF agents today, we have become aware of rare autoimmune complications as systemic lupus erythematosus and psoriasis, yet rarely has large vessels vasculitis been described. We herein describe a case of cytoplasmic anti-neutrophil cytoplasmic antibody (c-ANCA) (with myeloperoxidase (MPO) antibodies)-associated large vessel vasculitis (aortitis) that developed during anti-TNF treatment for ankylosing spondylitis. Awareness of this rare, but serious, adverse event of these commonly used agents in rheumatic diseases is of importance.
- Published
- 2015
- Full Text
- View/download PDF